Alkermes' alixorexton met key goals in a phase 2 study for narcolepsy type 2, showing significant improvements in wakefulness and sleepiness scores.

Alkermes' experimental drug significantly improved wakefulness and reduced excessive daytime sleepiness in patients with a rare sleep disorder in a mid-stage study, it said on Wednesday. Shares of the ...

Like many of the chemicals and processes powering our bodies, the composition of the microbiome naturally fluctuates ...